Medical Technology Development

Abstract

Guidance for Development of the Force - Medical Technology Development provides funds for promising candidate solutions that are selected for initial safety and effectiveness testing in animal studies and/or small scale human clinical trials regulated by the US Food and Drug Administration prior to licensing for human use. Research in this PE is designed to address the following: Secretary of Defense areas of interest regarding Wounded Warriors, capabilities identified through the Joint Capabilities Integration and Development System, and the strategy and initiatives described in the Quadrennial Defense Review. Program development and execution is peer-reviewed and fully coordinated with all of the Military Services, appropriate Defense Agencies or Activities and other federal agencies, to include the Department of Veterans Affairs, the Department of Health and Human Services, and the Department of Homeland Security. This coordination occurs through the planning and execution activities of the Joint Program Committees (JPCs), established for the Defense Health Program, Research Development Test and Evaluation (RDT&E) funding. Research supported by this PE includes polytrauma and blast injury, diagnosis and treatment of brain injury, environmental health and performance, physiological and psychological health, injury prevention and reduction, medical simulation and training, health informatics, and rehabilitation. For the Army Medical Command, the Hard Body Armor project focuses on scientific study and evaluation of injuries related to blunt trauma events on cadavers. Preventing blunt trauma injury is one of the critical components of body armor design. For the Army Medical Command, the Underbody Blast Testing medical research project provides funds to establish a scientific and statistical basis for evaluating skeletal injuries to vehicle occupants during ground vehicle Underbody Blast (UBB) events. Areas of interest to the Secretary of Defense are medical research that provides an understanding of the human tolerance limits and injury mechanisms needed to accurately predict skeletal injuries to ground combat vehicle occupants caused by UBB events. For the Navy Bureau of Medicine and Surgery, this program element includes funds for research management support costs. The Outside Continental US (OCONUS) laboratories conduct focused medical research on vaccine development for Malaria, Diarrhea Diseases, and Dengue Fever. In addition to entomology, HIV studies, surveillance and outbreak response under the Global Emerging Infections Surveillance (GEIS) program and risk assessment studies on a number of other infectious diseases that are present in the geographical regions where the laboratories are located. The CONUS laboratories conduct research on Military Operational Medicine, Combat Casualty Care, Diving and Submarine Medicine, Infectious Diseases, Environmental and Occupational Health, Directed Energy, and Aviation Medicine and Human Performance. For the Army Medical Command, beginning in FY14, military human immunodeficiency virus (HIV) research program funding is transferred from the Army to the Defense Health Program. This project funds research to develop candidate HIV vaccines, to assess their safety and effectiveness in human subjects, and to protect the military personnel from risks associated with HIV infection. In addition, the research is designed to find ways to protect the blood supply from contamination with HIV virus. For the Army Medical Command, the Armed Forces Pest Management Board (AFPMB) Deployed Warfighter Protection project provides for the development of new or improved protection of ground forces from disease carrying insects. For the Army Medical Command, four Centers of Excellence (CoE) receive Medical Technology Development funds. The Breast Cancer Center of Excellence (Army) provides a multidisciplinary approach as the standard of care for treating breast diseases and breast cancer. The Gynecologic Center of Excellence (Army) focuses on characterizing the molecular alterations associated with benign and malignant gynecologic disease and facilitates the development of novel early detection, prevention and novel biologic therapeutics for the management of gynecologic disease. The Cardiac Health Center of Excellence (Army) provides evidence-based personalized patient engagement approaches for comprehensive cardiac event prevention through education, outcomes research and technology tools, as well as molecular research to detect cardiovascular (CV) disease at an early stage to ultimately discover a signature for CV health, to find new genes that significantly increase risk for heart attack in Service members and other beneficiaries, and identify molecular markers of obesity and weight loss. The Pain Center of Excellence (Army) examines the relationship between acute and chronic pain and focuses on finding, implementing, and evaluating the most effective methods of relieving the acute pain caused by combat trauma and the effect this has throughout the continuum to rehabilitation and reintegration. For the Air Force Medical Service, funding in this program element supports the Air Force Surgeon General's vision for medical modernization through a robust research & development program. It funds advanced technology development within the following research thrust/project areas: Expeditionary Medicine, En-Route Care, Force Health Protection, Operational Medicine, and Human Performance, with the intent to support solutions that answer Air Force specific needs. During this process, the efforts of other government agencies in those areas will be assessed to avoid redundancy. For the Uniformed Services University of the Health Sciences (USUHS), Medical Development programs include the Neuroscience CoE, the Prostate Cancer CoE, and the Center for Neuroscience and Regenerative Medicine. The Neuroscience Center of Excellence (CoE), formerly a Congressional Special Interest program, was chartered in 2002 to conduct basic, clinical and translational research studies of militarily relevant neurological disorders affecting US service members and military medical beneficiaries. The Center’s mission is to improve prevention, diagnosis and treatment of neurological disorders that directly affect warfighters through a multi-site research program that collaborates broadly with military, civilian and federal medical institutions. The Prostate CoE, formerly a Congressional Special Interest program, was chartered in 1992 to conduct basic, clinical and translational research programs to combat diseases of the prostate. The program’s mission is fulfilled primarily through its three principal programs- the Clinical Translational Research Center, the Basic Science Research Program and the Tri-Service Multicenter Prostate Cancer Database which encompasses its clinical research work with other participating military medical centers. These affiliated sites contribute data and biospecimens obtained from prostate cancer patients and participate in clinical trials. The Center for Neuroscience and Regenerative Medicine (CNRM) brings together the expertise of clinicians and scientists across disciplines to catalyze innovative approaches to traumatic brain injury (TBI) research. CNRM Research Programs emphasize aspects of high relevance to military populations, with a primary focus on patients at the Walter Reed National Military Medical Center. In FY12, DHP funded the following Congressional Special Interest (CSI) peer-reviewed directed research: Amyotrophic Lateral Sclerosis (ALS); Autism; Bone Marrow Failure Disease; Ovarian Cancer; Multiple Sclerosis; Cancer; Lung Cancer; Orthopedic Research; Spinal Cord Research; Vision; Traumatic Brain Injury and Psychological Health; Breast Cancer; Prostate Cancer; Gulf War Illness; Alcohol and Substance Use Disorders; Medical Research; Alzheimer Research; Pain Management Task Force; Blast Recovery Monitors; Armed Forces Institute of Regenerative Medicine; Hemorrhage Control; Joint Warfighter Medical Research; Restorative Transplantation; Global HIV/AIDS Prevention; Tuberous Sclerosis Complex; and Duchenne Muscular Dystrophy. Because of the CSI annual structure, out-year funding is not programmed.

Open PDF

Document Details

Document Type: R2 Budgetary Justification
Publication Date: Oct 01, 2014
Source ID: 0603115HP_2_0130_PB_2014
Change Summary Explanation: FY 2012: Restore FY 2013 President’s Budget decrease to Congressional Special Interest from DHP RDT&E PE 0605502-Small Business Innovation Research (SBIR) Program (-$13.302 million) to DHP RDT&E, PE 0603115- Medical Technology Development (+$13.302 million). Realign DHP RDT&E, PE 0603115-Medical Technology Development (-$2.735 million) to DHP RDT&E PE 0605502-Small Business Innovation Research (SBIR) Program (+$2.735 million). FY 2013: No Change FY 2014: Change Proposal increase to DHP RDT&E, PE 0603115-Medical Technology Development (+$7.111 million) for the Military HIV Research Program (MHRP) from RDT&E, Army, appropriation.
Service Agency Name: Defense Health Program

Medical Technology Development

Abstract

Document Details

Tags

DTIC Thesaurus Topics

Fields of Study

Readers

Technology Areas

Related Documents